InsiderTrades.com logo
Jennifer L. Callahan net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jennifer Callahan Biography and Net Worth

Chief Financial Officer of Cingulate

Jennifer Callahan was named Cingulate’s Chief Financial Officer in January 2024. She brings decades of finance and accounting experience to the C-Suite, serving as Vice President, Corporate Controller for Cingulate from 2017 until her promotion to CFO. Prior to her role at the Company, Jennifer served as the Director of Accounting for a local Kansas City area CPA firm. Over the tenure of her career, she has provided consulting services to companies in a variety of industries and stages, publicly and privately owned. Jennifer started her career with Deloitte where she served in various roles in the audit practice. Ms. Callahan holds a CPA designation and received a BSBA in Accounting and Finance from Creighton University in Omaha, Nebraska.

What is Jennifer L. Callahan's net worth?

The estimated net worth of Jennifer L. Callahan is at least $26.28 thousand as of February 6th, 2026. Ms. Callahan owns 5,059 shares of Cingulate stock worth more than $26,282 as of September 18th. This net worth evaluation does not reflect any other investments that Ms. Callahan may own. Learn More about Jennifer L. Callahan's net worth.

How do I contact Jennifer L. Callahan?

The corporate mailing address for Ms. Callahan and other Cingulate executives is 1901 W. 47th Place, Kansas City, KS, 66205. Cingulate can also be reached via phone at 913-942-2300 and via email at [email protected]. Learn More on Jennifer L. Callahan's contact information.

Has Jennifer L. Callahan been buying or selling shares of Cingulate?

Jennifer L. Callahan has not been actively trading shares of Cingulate over the course of the past ninety days. Most recently, on Friday, February 6th, Jennifer L. Callahan bought 4,864 shares of Cingulate stock. The stock was acquired at an average cost of $5.04 per share, with a total value of $24,514.56. Following the completion of the transaction, the chief financial officer now directly owns 5,059 shares of the company's stock, valued at $25,497.36. Learn More on Jennifer L. Callahan's trading history.

Are insiders buying or selling shares of Cingulate?

In the last year, Cingulate insiders bought shares 5 times. They purchased a total of 130,350 shares worth more than $656,964.00. The most recent insider tranaction occured on February, 13th when Director Thomas Jeffrey Hargroves bought 97,276 shares worth more than $490,271.04. Insiders at Cingulate own 5.3% of the company. Learn More about insider trades at Cingulate.

Information on this page was last updated on 2/13/2026.

Jennifer L. Callahan Insider Trading History at Cingulate

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/6/2026Buy4,864$5.04$24,514.565,059View SEC Filing Icon  
3/15/2024Buy55$27.10$1,490.502,333View SEC Filing Icon  
9/15/2023Buy250$13.40$3,350.002,275View SEC Filing Icon  
5/15/2023Buy100$20.20$2,020.002,025View SEC Filing Icon  
5/12/2023Buy200$21.60$4,320.001,925View SEC Filing Icon  
12/14/2022Buy377$19.80$7,464.601,725View SEC Filing Icon  
11/28/2022Buy174$19.60$3,410.401,271View SEC Filing Icon  
9/8/2022Buy175$30.00$5,250.001,097View SEC Filing Icon  
3/16/2022Buy95$27.80$2,641.00View SEC Filing Icon  
3/14/2022Buy600$29.20$17,520.00View SEC Filing Icon  
See Full Table

Jennifer L. Callahan Buying and Selling Activity at Cingulate

This chart shows Jennifer L. Callahan's buying and selling at Cingulate by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cingulate Company Overview

Cingulate logo
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Read More

Today's Range

Now: $5.26
Low: $5.09
High: $5.21

50 Day Range

MA: $5.03
Low: $4.43
High: $5.87

2 Week Range

Now: $5.26
Low: $3.16
High: $11.89

Volume

38,432 shs

Average Volume

410,439 shs

Market Capitalization

$76.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A